Latest

Cellworks Singula™ TRI Provides Superior OS Predictions for NSCLC Patients Beyond NCCN-guideline Genomic Factors

Cellworks: Predictions of Overall Survival And Progression-Free Survival For Therapeutic Interventions In Glioblastoma Multiforme

OncoResponse Mines PD-1 Therapy “Elite Responders” For IO Breakthroughs

Wall Street Journal: Behind a New Pill to Treat Covid: A Husband-and-Wife Team and a Hunch

Wall Street Journal: Merck’s Covid-19 Drug Is a Boon for Wall Street and Main Street

Atea Announces Publication of Data Highlighting AT-752’s Potent Activity Against Dengue and Other Flaviviruses

COVID-19 viral biotech Atea Pharmaceuticals prices upsized IPO at $24 high end